AUTL has been the subject of several other reports. Truist Financial increased their price objective on Autolus Therapeutics from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, August 17th. Deutsche Bank Aktiengesellschaft assumed coverage on Autolus Therapeutics in a report on Thursday, November 9th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $7.00 price target on shares of Autolus Therapeutics in a research report on Wednesday, October 25th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics currently has an average rating of “Buy” and a consensus price target of $8.17.
Autolus Therapeutics Stock Up 2.6 %
Institutional Trading of Autolus Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of AUTL. Perpetual Ltd boosted its stake in Autolus Therapeutics by 7.4% in the second quarter. Perpetual Ltd now owns 1,996,355 shares of the company’s stock worth $4,751,000 after buying an additional 138,264 shares in the last quarter. Boulder Hill Capital Management LP purchased a new stake in Autolus Therapeutics in the first quarter worth about $105,000. B. Riley Wealth Advisors Inc. purchased a new stake in Autolus Therapeutics in the second quarter worth $52,000. Exchange Traded Concepts LLC purchased a new stake in Autolus Therapeutics in the second quarter worth $118,000. Finally, Rathbones Group PLC bought a new position in Autolus Therapeutics in the third quarter worth $171,000. Hedge funds and other institutional investors own 64.78% of the company’s stock.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
- Five stocks we like better than Autolus Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- Amazon, Target, Walmart in a race for fastest delivery
- What is a Secondary Public Offering? What Investors Need to Know
- Palo Alto Networks: the one security stock to rule them all
- How to Invest in Solar Energy
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.